These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 35812415)

  • 21. Sialic acid removal from dendritic cells improves antigen cross-presentation and boosts anti-tumor immune responses.
    Silva M; Silva Z; Marques G; Ferro T; Gonçalves M; Monteiro M; van Vliet SJ; Mohr E; Lino AC; Fernandes AR; Lima FA; van Kooyk Y; Matos T; Tadokoro CE; Videira PA
    Oncotarget; 2016 Jul; 7(27):41053-41066. PubMed ID: 27203391
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Artificial human antigen-presenting cells are superior to dendritic cells at inducing cytotoxic T-cell responses.
    Li H; Shao S; Cai J; Burner D; Lu L; Chen Q; Minev B; Ma W
    Immunology; 2017 Nov; 152(3):462-471. PubMed ID: 28664991
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Antigen presentation and immune regulatory capacity of immature and mature-enriched antigen presenting (dendritic) cells derived from human bone marrow.
    Jin Y; Fuller L; Ciancio G; Burke GW; Tzakis AG; Ricordi C; Miller J; Esquenzai V
    Hum Immunol; 2004 Feb; 65(2):93-103. PubMed ID: 14969764
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Application of biomimetic nanovaccines in cancer immunotherapy: A useful strategy to help combat immunotherapy resistance.
    Xu Z; Zhou H; Li T; Yi Q; Thakur A; Zhang K; Ma X; Qin JJ; Yan Y
    Drug Resist Updat; 2024 Jul; 75():101098. PubMed ID: 38833804
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Nanovaccine based on a protein-delivering dendrimer for effective antigen cross-presentation and cancer immunotherapy.
    Xu J; Wang H; Xu L; Chao Y; Wang C; Han X; Dong Z; Chang H; Peng R; Cheng Y; Liu Z
    Biomaterials; 2019 Jul; 207():1-9. PubMed ID: 30947117
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cascade Cytosol Delivery of Dual-Sensitive Micelle-Tailored Vaccine for Enhancing Cancer Immunotherapy.
    Jiang D; Mu W; Pang X; Liu Y; Zhang N; Song Y; Garg S
    ACS Appl Mater Interfaces; 2018 Nov; 10(44):37797-37811. PubMed ID: 30360105
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cooperating minimalist nanovaccine with PD-1 blockade for effective and feasible cancer immunotherapy.
    Jiang M; Zhao L; Cui X; Wu X; Zhang Y; Guan X; Ma J; Zhang W
    J Adv Res; 2022 Jan; 35():49-60. PubMed ID: 35003793
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Use of two predictive algorithms of the world wide web for the identification of tumor-reactive T-cell epitopes.
    Lu J; Celis E
    Cancer Res; 2000 Sep; 60(18):5223-7. PubMed ID: 11016651
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Inactivation of tumor-specific CD8⁺ CTLs by tumor-infiltrating tolerogenic dendritic cells.
    Harimoto H; Shimizu M; Nakagawa Y; Nakatsuka K; Wakabayashi A; Sakamoto C; Takahashi H
    Immunol Cell Biol; 2013 Oct; 91(9):545-55. PubMed ID: 24018532
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Enhanced presentation of MHC class Ia, Ib and class II-restricted peptides encapsulated in biodegradable nanoparticles: a promising strategy for tumor immunotherapy.
    Ma W; Smith T; Bogin V; Zhang Y; Ozkan C; Ozkan M; Hayden M; Schroter S; Carrier E; Messmer D; Kumar V; Minev B
    J Transl Med; 2011 Mar; 9():34. PubMed ID: 21450109
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The infection of human dendritic cells with recombinant avipox vectors expressing a costimulatory molecule transgene (CD80) to enhance the activation of antigen-specific cytolytic T cells.
    Tsang KY; Zhu M; Even J; Gulley J; Arlen P; Schlom J
    Cancer Res; 2001 Oct; 61(20):7568-76. PubMed ID: 11606396
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Antibody-mediated delivery of a viral MHC-I epitope into the cytosol of target tumor cells repurposes virus-specific CD8
    Jung K; Son MJ; Lee SY; Kim JA; Ko DH; Yoo S; Kim CH; Kim YS
    Mol Cancer; 2022 Apr; 21(1):102. PubMed ID: 35459256
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Artificial antigen-presenting cells are superior to dendritic cells at inducing antigen-specific cytotoxic T lymphocytes.
    Shao J; Xu Q; Su S; Wei J; Meng F; Chen F; Zhao Y; Du J; Zou Z; Qian X; Liu B
    Cell Immunol; 2018 Dec; 334():78-86. PubMed ID: 30392890
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Antigen processing and presentation.
    Kotsias F; Cebrian I; Alloatti A
    Int Rev Cell Mol Biol; 2019; 348():69-121. PubMed ID: 31810556
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Nanovaccine Incorporated with Hydroxychloroquine Enhances Antigen Cross-Presentation and Promotes Antitumor Immune Responses.
    Liu J; Liu X; Han Y; Zhang J; Liu D; Ma G; Li C; Liu L; Kong D
    ACS Appl Mater Interfaces; 2018 Sep; 10(37):30983-30993. PubMed ID: 30136844
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Antigen presentation and T cell stimulation by dendritic cells.
    Guermonprez P; Valladeau J; Zitvogel L; Théry C; Amigorena S
    Annu Rev Immunol; 2002; 20():621-67. PubMed ID: 11861614
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Engineering anti-cancer nanovaccine based on antigen cross-presentation.
    Warrier VU; Makandar AI; Garg M; Sethi G; Kant R; Pal JK; Yuba E; Gupta RK
    Biosci Rep; 2019 Oct; 39(10):. PubMed ID: 31652460
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Preparation of fully activated dendritic cells capable of priming tumor-specific cytotoxic T lymphocytes in patients with metastatic cancer using penicillin-killed streptococcus pyogenes (OK432) and anti-CD40 antibody.
    Kontani K; Teramoto K; Ozaki Y; Sawai S; Tezuka N; Ishida H; Kajino K; Fujino S; Yamauchi A; Taguchi O; Kannagi R; Yokomise H; Ogasawara K
    Oncol Rep; 2007 Apr; 17(4):895-902. PubMed ID: 17342333
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Nanobiomaterial-based vaccination immunotherapy of cancer.
    Chen F; Wang Y; Gao J; Saeed M; Li T; Wang W; Yu H
    Biomaterials; 2021 Mar; 270():120709. PubMed ID: 33581608
    [TBL] [Abstract][Full Text] [Related]  

  • 40. STING-activating dendritic cell-targeted nanovaccines that evoke potent antigen cross-presentation for cancer immunotherapy.
    Nguyen NT; Le XT; Lee WT; Lim YT; Oh KT; Lee ES; Choi HG; Youn YS
    Bioact Mater; 2024 Dec; 42():345-365. PubMed ID: 39290338
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.